Revolution Medicines Statistics
Total Valuation
RVMD has a market cap or net worth of $19.64 billion. The enterprise value is $18.05 billion.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RVMD has 198.17 million shares outstanding. The number of shares has increased by 13.35% in one year.
| Current Share Class | 198.17M |
| Shares Outstanding | 198.17M |
| Shares Change (YoY) | +13.35% |
| Shares Change (QoQ) | +3.93% |
| Owned by Insiders (%) | 2.34% |
| Owned by Institutions (%) | 93.88% |
| Float | 178.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 11.97 |
| P/TBV Ratio | 12.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.14, with a Debt / Equity ratio of 0.26.
| Current Ratio | 7.14 |
| Quick Ratio | 6.97 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -48.80 |
Financial Efficiency
Return on equity (ROE) is -58.07% and return on invested capital (ROIC) is -33.14%.
| Return on Equity (ROE) | -58.07% |
| Return on Assets (ROA) | -30.08% |
| Return on Invested Capital (ROIC) | -33.14% |
| Return on Capital Employed (ROCE) | -57.28% |
| Weighted Average Cost of Capital (WACC) | 9.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 883 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +153.40% in the last 52 weeks. The beta is 1.01, so RVMD's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +153.40% |
| 50-Day Moving Average | 102.51 |
| 200-Day Moving Average | 63.71 |
| Relative Strength Index (RSI) | 49.50 |
| Average Volume (20 Days) | 2,279,142 |
Short Selling Information
The latest short interest is 14.11 million, so 7.12% of the outstanding shares have been sold short.
| Short Interest | 14.11M |
| Short Previous Month | 13.66M |
| Short % of Shares Out | 7.12% |
| Short % of Float | 7.89% |
| Short Ratio (days to cover) | 5.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | -987.33M |
| Operating Income | -1.18B |
| Pretax Income | -1.13B |
| Net Income | -1.13B |
| EBITDA | -1.17B |
| EBIT | -1.18B |
| Earnings Per Share (EPS) | -$5.95 |
Full Income Statement Balance Sheet
The company has $2.03 billion in cash and $427.15 million in debt, with a net cash position of $1.60 billion or $8.07 per share.
| Cash & Cash Equivalents | 2.03B |
| Total Debt | 427.15M |
| Net Cash | 1.60B |
| Net Cash Per Share | $8.07 |
| Equity (Book Value) | 1.63B |
| Book Value Per Share | 8.28 |
| Working Capital | 1.78B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$897.74 million and capital expenditures -$15.99 million, giving a free cash flow of -$913.73 million.
| Operating Cash Flow | -897.74M |
| Capital Expenditures | -15.99M |
| Free Cash Flow | -913.73M |
| FCF Per Share | -$4.61 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RVMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.35% |
| Shareholder Yield | -13.35% |
| Earnings Yield | -5.76% |
| FCF Yield | -4.65% |
Dividend Details Analyst Forecast
The average price target for RVMD is $117.33, which is 17.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $117.33 |
| Price Target Difference | 17.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |